Clinical Trial Search

Primary: To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2). — 95; 3; 3; 3…

Primary: Post-Operative Pain — 2.9; 3.0 units on a scale — p=0.76

Primary: Change in Central Systolic Blood Pressure (SBP) — 125.3; 127.8; 121.6; 123.8 mmHg

Primary: Measures of Liver Function: AST and ALT — 36.2; 52; 31.7; 57.86 IU/L

Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants

Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline — 33.1; 5.3 percentage of…

Primary: Mean Number of Standard Drinks Per Drinking Day During the Last 4 Weeks of the Trial — 0.6; 3.8 standard drinks/drinking day

Primary: Clinical Global Impressions Scale - Improvement - Social — 3; 1 participants

Primary: Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline — 28.8; 5.8…

Primary: Number of Participants With a Change in Bladder Pressure — 0 participants

Primary: Overall Survival (OS) - Percentage of Participants With an Event — 62.8; 56.8 percentage of participants

Primary: Incidence of Clinically Significant Osteolysis — 0; 15 unrevised THAs

Primary: Patient Engagement — 68.14 text message response rate (percent)

Primary: Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum — 0.01; -0.02…

Primary: Mean Ocular Itching Score Compared to Placebo Period1 — 0.4; 1.7 score — p=<0.001